NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHLBI E-191-2020-0-EP-04 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT EP National Stage 21845838.8 Pending
NCI E-172-2020-0-JP-01 HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION JP National Stage 2023-503124 Pending
NCI E-045-2022-0-PCT-02 Method of HLA loss Heterozygosity Detection in Liquid Biopsies PCT PCT PCT/US2023/060664 Pending
NIAID E-251-2016-0-US-05 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE US DIV 18/154,745 Pending
NINDS E-130-2022-3-JP-02 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE JP DIV 2023-003205 Pending
NCI E-165-2020-0-JP-01 HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D
MUTATION 		JP National Stage 2023-502572 Pending
NCI E-165-2020-0-US-02 HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation US National Stage 18/015,776 Pending
NCI E-172-2020-0-US-02 HLA Class-II Restricted DRB1*01:01 T-cell Receptors Against The RASG12V Mutation US National Stage 18/015,781 Pending
NIAID E-104-2020-0-CN-05 RSV VACCINE BEARING ONE OF MORE P GENE MUTATIONS CN National Stage 202180061234.5 Pending
NCI E-172-2020-0-AU-01 HLA Class-II Restricted DRB1*01:01 T-cell Receptors Against The RASG12V Mutation AU National Stage 2021309958 Pending
NCI E-051-2022-0-PCT-02 Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of their Tumors PCT PCT PCT/US2023/060416 Pending
NCI E-172-2020-0-CA-01 HLA Class-II Restricted DRB1*01:01 T-cell Receptors Against The RASG12V Mutation CA National Stage 3185483 Pending
NHLBI E-011-2016-0-US-01 CLOSED-ENDED, LINEAR, DUPLEX ADENOASSOCIATED VIRUS DNA, AND USES THEREOF US CON 18/151,803 Pending
NHLBI E-206-2020-0-US-02 Devices And Methods For Cerclage Of Luminal Systems US National Stage 18/151,601 Pending
NCATS E-057-2022-0-PC-01 ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF PCT PCT PCT/US2023/060233 Pending
NHLBI E-144-2021-0-PC-01 Tissue Cutting Systems and Methods PCT PCT PCT/US2023/060223 Pending
NCI E-059-2013-0-US-02 METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR REACTIVE T CELLS FROM TUMOR US CON 18/093,902 Pending
NCI E-172-2020-0-SG-01 HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS
WITH G12V MUTATION 		SG National Stage 11202300139Y Pending
NCI E-165-2020-0-SG-01 HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation SG National Stage 11202300142Y Pending
NCI E-165-2020-0-CA-01 HLA Class-II Restricted DRB T-cell Receptors Against The RASG12D Mutation CA National Stage 3185241 Pending
NIAID E-088-2022-0-PC-01 Novel Immunogens For Influenza Virus Vaccines PCT PCT PCT/US2023/060130 Pending
NCI E-078-2020-0-EP-05 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM EP National Stage 21822452.5 Pending
NIAAA E-316-2013-0-US-03 Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate US CON 18/149,300 Pending
NEI E-071-2020-0-US-08 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION US National Stage 18/014,045 Pending
NHGRI E-034-2022-0-PCT-02 GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA PCT PCT PCT/US2022/082527 Pending
NCI E-046-2022-0-PCT-02 Neoantigen T Cell Therapy With Neoantigen Vaccination As A Combination Immunotherapy Against Cancer PCT PCT PCT/US2022/082579 Pending
NCI E-233-2014-0-US-23 METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION US DIV 18/147,786 Pending
NHGRI E-034-2022-0-US-02 GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA US National Stage
NHGRI E-034-2022-0-EP-01 GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA EP National Stage
NEI E-071-2020-0-JP-07 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME JP National Stage 2022-581456 Pending
NINDS E-120-2020-2-US-02 ADAPTABLE DUAL-TUNED OPTICALLY CONTROLLED ON-COIL AMPLIFIER FOR
HIGH-FIELD MAGNETIC RESONANCE IMAGING SYSTEMS 		US National Stage 18/013,042 Pending
NHGRI E-044-2013-1-MO-01 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA MO CN J/6735 Issued
NCI E-244-2015-0-CN-22 Brachyury Deletion Mutants, Non-Yeast Vectors Encoding Brachyury Deletion Mutants, and Their Use CN DIV 202211664625.9 Pending
NCATS E-026-2016-0-EA-01 Compounds for Improving MRNA Splicing EA DIV 202293446 Pending
NCI E-210-2020-0-US-01 AGENTS FOR SENSITIZING SOLID TUMORS TO TREATMENT US National Stage 18/012,260 Pending
NIDDK E-085-2022-0-PC-01 NEXT GENERATION TRANSPOSOSOMES PCT PCT PCT/US2022/082217 Pending
NCATS E-022-2022-0-PCT-02 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		PCT PCT PCT/US2022/082171 Pending
NCI E-152-2020-0-US-03 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 US National Stage 18/012,056 Pending
NINDS E-201-2020-0-US-04 Nanobodies Directed to Coronavirus Spike Protein Receptor for Binding Domain and Uses Thereof US National Stage 18/011,767 Pending
NCATS E-136-2020-0-US-07 METHOTREXATE ANALOGS AND METHODS OF USE US National Stage 18/011,288 Pending
NCI E-033-2022-0-US-02 Mab 15B6 Blocks Mesothelin Shedding And Makes Very Active CAR-T Cell And BITE US National Stage Pending
NCI E-033-2022-0-CA-01 Mab 15B6 Blocks Mesothelin Shedding And Makes Very Active CAR-T Cell And BITE CA National Stage Pending
NCI E-033-2022-0-AU-01 Mab 15B6 Blocks Mesothelin Shedding And Makes Very Active CAR-T Cell And BITE AU National Stage Pending
NCI E-033-2022-0-PCT-02 Mab 15B6 Blocks Mesothelin Shedding And Makes Very Active CAR-T Cell And BITE PCT PCT PCT/US2022/081766 Pending
NCI E-033-2022-0-EP-01 Mab 15B6 Blocks Mesothelin Shedding And Makes Very Active CAR-T Cell And BITE EP National Stage Pending
NIAAA E-191-2021-0-PCT-02 SULFONAMIDE DERIVATIVES AND THEIR USE AS SOLUBLE EPOXIDE
HYDROLASE INHIBITORS 		PCT PCT PCT/US2022/052957 Pending
NICHD E-184-2021-0-PCT-02 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO PCT PCT PCT/US2022/052704 Pending
NCI E-113-2021-0-PCT-02 vBacteriophage Based-Vaccine System PCT PCT PCT/US2022/081383 Pending
NIAID E-104-2020-0-IN-07 RSV VACCINE BEARING ONE OF MORE P GENE MUTATIONS IN National Stage 202247071505 Pending
NCI E-078-2020-0-US-06 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM US National Stage 18/009,710 Pending